title: Effects of prostaglandin analogues on aqueous humor outflow pathways.
abstract: Elevated intraocular pressure (IOP) is the most prevalent risk factor for glaucoma. All treatments, whether surgical or pharmaceutical, are aimed at lowering IOP. Prostaglandin analogues are a first line therapy for glaucoma due to their ability to reduce IOP, once-daily dosing, efficacy, and minimal side-effect profile. Whereas prostaglandin analogues have been known to alter aqueous humor outflow through the unconventional (uveoscleral) pathway, more recent evidence suggests their action also occurs through the conventional (trabecular) pathway. Understanding how prostaglandin analogues successfully lower IOP is important, as this information may lead to the discovery of new molecular targets for future therapeutic intervention. This review explores the current understanding of prostaglandin analogue biology as it pertains to IOP reduction and improved aqueous humor outflow facility.
authors.affiliation: 1 Mayo Clinic College of Medicine , Rochester, Minnesota.
authors.forename: Nelson S
authors.initials: NS
authors.lastname: Winkler
authors.forename: Michael P
authors.initials: MP
authors.lastname: Fautsch
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001082:Aqueous Humor / Q000187:drug effects* / Q000378:metabolism; D015195:Drug Design; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D011465:Prostaglandins, Synthetic / Q000494:pharmacology*; D012307:Risk Factors
chemical_list: D000959:Antihypertensive Agents; D011465:Prostaglandins, Synthetic